Cure8 research brief
Sarcopenia (low muscle mass) was linked with worse outcomes in Crohn’s disease and, combined with fecal calprotectin and disease behaviour, formed a score that better predicted unfavourable courses. Identifying at-risk patients could guide nutritional support and closer monitoring.
Adults with Crohn’s disease; gastroenterologists and IBD clinicians; dietitians/nutritionists; researchers focused on prognostic biomarkers in IBD.
This retrospective observational study of hospitalized Crohn’s disease patients used prior CT scans to measure skeletal muscle area/index and tested whether sarcopenia predicts an unfavourable clinical course.
The authors report that low skeletal muscle index (sarcopenia), faecal calprotectin >129 µg/g, and complicated disease behaviour (Montreal B2/B3) were independent predictors, and a composite score combining these factors had higher predictive accuracy (AUROC 0.864) than single markers.
The paper is hypothesis-generating: it suggests routine nutritional/muscle-mass assessment could help identify higher-risk patients who might benefit from targeted nutritional interventions, but the finding comes from a single retrospective cohort (n=52) and needs prospective validation.
If you or a clinician is considering assessing muscle mass, this study used CT-based skeletal muscle index measurements and faecal calprotectin as objective measures—tools that require radiologic and laboratory resources and interpretation.
Retrospective single-centre cohort (52 patients) and abstract-summary depth mean findings are preliminary and need prospective validation before changing clinical practice.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Non-invasive fecal lipid markers could help differentiate UC from CD and improve diagnostic molecular profiling in IBD if validated, which may be useful for patients and clinicians seeking less-invasive diagnostic tools.
If validated, blood microRNAs could become noninvasive biomarkers to help track inflammation and predict biochemical response to infliximab or vedolizumab in Crohn’s disease, complementing CRP and fecal calprotectin.
This model aims to identify healthy first‑degree relatives at higher risk of developing Crohn’s disease before symptoms start, which could enable earlier monitoring or preventive strategies. The score uses simple...
